Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:17:52 UTC, with 37 holding rows worth $1,290,641,676.

Accession
0001831942-26-000052
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 37 entries on the cover page, a total value of $1,290,641,676 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,290,641,676 with VALUE read as dollars as filed, 13F file number 028-20976. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
RELAY THERAPEUTICS INC COM75943R102Stock12,000,000$216,600,000dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock3,275,000$150,126,000dollars as filed
ALKERMES PLCG01767105SHS2,875,360$116,509,587dollars as filed
ALTO NEUROSCIENCE INC COM SHS02157Q109Stock2,723,196$69,523,194dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW700,000$62,321,000dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM2,000,000$58,200,000dollars as filed
LB PHARMACEUTICALS INC50180M108COMMON STOCK1,282,273$49,213,638dollars as filed
DAMORA THERAPEUTICS INCG2646Y104COMM STK1,939,000$41,261,920dollars as filed
COGENT BIOSCIENCES INC19240Q201COM1,265,000$40,505,300dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK1,725,000$37,725,750dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,000,000$32,410,000dollars as filed
PHARVARIS NVN69605108COMMON STOCK925,000$29,341,000dollars as filed
SURROZEN INC86889P208COMMON STOCK885,000$28,479,300dollars as filed
KORSANA BIOSCIENCES INC23255M303COMMON STOCK877,022$28,064,704dollars as filed
SAGIMET BIOSCIENCES INC A786700104COMMON STOCK2,757,742$27,246,491dollars as filed
DEFINIUM THERAPEUTICS INC24477V105COM SHS700,000$26,642,000dollars as filed
ADARx Pharmaceuticals, Inc.00654F105Common Stock, par value $0.0001 per share1,260,577$25,135,905dollars as filed
EDITAS MEDICINE INC28106W103COM8,889,000$22,844,730dollars as filed
ENTERA BIO LTDM40527109SHS7,352,941$21,397,058dollars as filed
ATTOVIA THERAPEUTICS INC04987L102COM1,160,000$19,882,400dollars as filed
AGENUS INC00847G804COM NEW1,985,387$19,714,893dollars as filed
KYMERA THERAPEUTICS INC501575104COM175,000$19,563,250dollars as filed
Inflarx NvN44821101COM9,268,220$16,682,796dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK1,018,319$15,610,830dollars as filed
AN2 THERAPEUTICS INC037326105COM2,933,680$15,607,178dollars as filed
CENTURY THERAPEUTICS INC15673T100COM8,695,652$14,869,565dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK3,250,000$13,520,000dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK5,397,488$11,091,838dollars as filed
ASSEMBLY BIOSCIENCES INC045396207COMMON STOCK461,922$10,850,548dollars as filed
PEPGEN INC COM713317105Stock4,475,000$10,829,500dollars as filed
SAB BIOTHERAPEUTICS INC78397T202COMMON STOCK2,870,000$9,097,900dollars as filed
RELMADA THERAPEUTICS INC75955J402COMMON STOCK2,350,000$8,859,500dollars as filed
RESEARCH ALLIANCE CORP IVG75228109CL A ORD SHS500,000$5,785,000dollars as filed
HELIX ACQUISITION CORP IIIG4444S107USD CL A ORD SHS500,000$5,310,000dollars as filed
JATT III ACQUISITION CORPG5080G109COM400,000$4,408,000dollars as filed
TCGX ACQUISITION CORPG8708J109COM300,000$3,753,000dollars as filed
LeonaBio Inc04746L203COM464,398$1,657,901dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-26-000052this filing2026-11-16